Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND: Avosentan in Diabetic Nephropathy
NCT00120328Phase 3Terminated
- Sponsor
- Speedel
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of avorsentan in diabetic nephropathy (DN) (3 arms), sponsored by Speedel. Primary endpoint: Time to doubling of serum creatinine, End Stage Renal Disease (ESRD) or Death. Started Jul 2005; status: terminated.
02
Drugs
avorsentan
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT00120328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00120328.